Duke Clinical Research Institute

New data from the DCRI-led RACE CARS Trial showed that with 911 intervention, bystanders performed CPR on women 44% of the time and on men 40% of the time. Without this guidance, these rates dropped to 9% for women and 11% for men. Read more about the findings, presented earlier this month at the American Heart Association’s Resuscitation Science Symposium: https://lnkd.in/eBg5M96j #clinicaltrials #clinicalresearch #cpr #heartattack

The DCRI is looking for two new Data Science and Biostatistics faculty members to join our team! Interested in applying, or know someone who may be a good fit? Check out the links on our Careers page to learn more and apply/share: https://lnkd.in/ejZNiVBD #clinicalresearch #nowhiring #biostats #datascience

Over 37 million adults in the U.S. have chronic kidney disease – yet racial disparities mean not everyone faces the same risks. A new research consortium led by the DCRI and The Samuel DuBois Cook Center on Social Equity at Duke University is focusing on addressing the striking disparities in kidney health linked to structural racism. Learn more: https://lnkd.in/ejY2K4Pg #clinicalresearch #healthequity #kidneydisease #structuralracism

FDA Commissioner and founding director of the DCRI Robert Califf sat down with current DCRI Executive Director Adrian Hernandez for a discussion about his life, work, mentors, and the emergence of data-drive research in this new episode of Duke University’s Centennial Oral Histories. Click the link to watch the full video: https://lnkd.in/ebA4Du2N #clinicalresearch #clinicaltrials #duke

That's the end of #AHA24 for the DCRI! Congratulations to our faculty, fellows, and staff for making the event such a great one. Stay tuned for our session recaps and more info on recently-presented research! #clinicaltrials #clinicalresearch #cardiology

DCRI's Jonathan Piccini, MD, MHS analyzed the key strengths and weaknesses of the #AHA24 late-breaker PROMPT-AF - a pivotal trial that confirms the efficacy seen in the previous VENUS trial, demonstrating that a more extensive ablation strategy can be an important treatment option for persistent #AFib patients. However, key questions remain about patient selection and whether benefits would be the same for those treated with pulsed-field ablation. #clinicalresearch #ablation 

Taking the 'pro' stance at #AHA24, DCRI's Karen Alexander made a compelling case for statins for primary prevention in adults age 75+. Heart disease & dementia loom large in late life, and data shows statins may reduce CV events, especially in those with CAC. #clinicaltrials #cardiovascular #statins

During a session on best practices in Acute Coronary Syndrome (ACS), DCRI’s Jennifer Rymer responded to questions about patients lost to follow-up. Reflecting on her experience doing procedures in a rural community, she urged the audience to consider patient access and affordability when prescribing so that the patient is setup for success.   #cardiology #patientcare #prescriptions

At #AHA24 this weekend, DCRI's Adrian Hernandez received the Outstanding Lifetime Achievement Award from the American Heart Association's Quality of Care and Outcomes Research Council. The annual award is presented to a QCOR Council member for their significant long-term contributions to outcomes research and the improvement of cardiovascular care. Read more: https://lnkd.in/eYPmY5Ew #clinicaltrials #clinicalresearch #cardiovascular

Despite the tremendous benefit of newer medications to treat diabetes and ASCVD, only 20-25% of patients are on high-intensity statins, half are on ACE/ARBs, and less than 10% are on SGLT2s or GLP1s. During #AHA24, DCRI's Neha Pagidipati highlighted the implementation lessons of the COORDINATE-Diabetes study and DRIVE trial that demonstrated a respective 23% and 65% increase in prescription rates. #clinicaltrials #clinicalresearch #diabetes